Apoa1 Antibody

1. both the route of administration and the formulation of apoA-I peptide significantly affect its pharmacokinetics and pharmacodynamics. PMID: 27881716
2. ABCA1 is diminished and ABCG1 is increased by N-acetylcysteine, which counteracts the reduction in apo A-I-mediated cholesterol efflux PMID: 25305669
3. Apolipoprotein A-I induces tubulin phosphorylation in association with cholesterol release in fetal rat astrocytes. PMID: 24814947
4. ApoA-I may be a protective blood-borne factor involved in the remote ischemic preconditioning mechanism. PMID: 24155931
5. It maintains cholesterol homeostasis. PMID: 24117066
6. on neonatal rat ventricular cardiomyocytes, the aldosterone-dependent chronotropic effects of antiapoA-1 IgG involve the nongenomic activation of L-type calcium channels PMID: 22253414
7. translocation of cholesterol and phospholipid into the cytosol is related to the apo A-I-mediated HDL assembly in astrocytes through functional association with caveolin-1 and a cyclosporin A-sensitive cyclophilin protein(s). PMID: 11773045
8. ABCA1-dependent cholesterol mobilization to apoA-I increased new cholesterol synthesis, indicating depletion of the regulatory pool of hepatocyte cholesterol during HDL formation PMID: 14993246
9. The association of CLPP with microtubules is mediated by caveolin-1, induced by apoA-I and regulates intracellular cholesterol trafficking for assembly of cellular lipids to apoA-I-HDL. PMID: 16606364
10. Data show that a complex of apolipoprotein A-I and pregnenolone modulate the rate of protein biosynthesis in liver cells. PMID: 18457017
11. ApoA-I reduced I/R-induced inflammatory responses, decreased renal microscopic damage and improved renal function. ApoA-I protects kidney from I/R injury by inhibiting inflammatory cytokines release and neutrophil infiltration and activation. PMID: 18535924

Show More

Hide All

KEGG: rno:25081

STRING: 10116.ENSRNOP00000065206

UniGene: Rn.10308